Effective and Rapid Osteoclast Inhibition by Denosumab, is Reflected in Serum C Telopeptide (CTX), Across Different Tumor Types
DOI:
https://doi.org/10.6000/1927-7229.2013.02.02.1Keywords:
Bone metastases, denosumab, serum c telopeptide.Abstract
Denosumab, a monoclonal antibody against RANKL has superior efficacy against bone metastases. Its in vivo activity can be measured recently by dosing of serum C telopeptide, produced by collagen destruction by the osteoclast. We report the first patient series, across several tumor types of the efficacy of denosumab in normalising serum CTX.
References
Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012; [Epub ahead of print]. http://dx.doi.org/10.1093/annonc/mds175
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379(9810): 39-46. http://dx.doi.org/10.1016/S0140-6736(11)61226-9
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28(35): 5132-39. http://dx.doi.org/10.1200/JCO.2010.29.7101
Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12(4): 1221-28. http://dx.doi.org/10.1158/1078-0432.CCR-05-1933
Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97 (3 Suppl): 887-92. http://dx.doi.org/10.1002/cncr.11138
Clemons M, Gelmo, KA, Pritchard KI, Paterson AH. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 2012; 19(5): 259-68. http://dx.doi.org/10.3747/co.19.1011
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1): 59-69. http://dx.doi.org/10.1093/jnci/dji002
Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012; 6: 89-99.
Dekoninck J, Geurs F, Deloecker R, Deprest Y. Significant pain relief with loading dose zoledronic acid in bone metastases is only seen in patients with elevated initial serum C telopeptide (CTX). Pragm Observ Res 2011; 2: 1-6.
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Simona Di Francesco, Raffaele L. Tenaglia, Metabolic Alterations, Vascular Disease and Advanced Prostate Cancer: New Players for Metastatic Advanced Prostate Cancer? , Journal of Analytical Oncology: Vol. 3 No. 1 (2014)
- B. Raggiunti, A. Franchi, V. Congedo, S. Filipponi, G. Fiore, G. Raggiunti, D. Tina, A. Mongia, A. Rufo, F.A. Ruggieri , D. Di Michele , Mixed Medullary Papillary Thyroid Carcinoma in Hyperfunctioning Hot Nodule: A Case Report and Review of the Literature , Journal of Analytical Oncology: Vol. 3 No. 3 (2014)
- Sven Wenske , Philippa Cheetham, Aaron E. Katz, Clinical and Biochemical Outcomes of High-Risk Prostate Cancer Patients treated with Third Generation Prostate Cryosurgery , Journal of Analytical Oncology: Vol. 2 No. 2 (2013)
- Guan Min Lai, Jen-Tsun Lin , Cheng-Shyong Chang , Metastatic Bone Marrow Tumors Manifested by Hematologic Disorders: Study of Thirty-Four Cases and Review of Literature , Journal of Analytical Oncology: Vol. 3 No. 4 (2014)
- Rajesh Javarappa, Ramesh Bilimagga, V. Chendil, B.R. Kiran Kumar, Amrut S. Kadam, Acute Haematological Variations in Patients Receiving Radiotherapy and its Correlation with Volume of the Bone Marrow and Radiation Dose , Journal of Analytical Oncology: Vol. 9 (2020)
- Omar Youssef, Virinder Kaur Sarhadi, Lauri Lehtimäki, Milja Tikkanen, Arto Kokkola, Pauli Puolakkainen, Gemma Armengol, Sakari Knuutila, Peritoneal Carcinomatosis and Multi-Organ Metastases are Prognostic Factors in Colorectal Cancer: A Retrospective Analysis , Journal of Analytical Oncology: Vol. 5 No. 1 (2016)
- Mª José Safont, Jorge Aparicio, Alejandra Giménez Ortiz, José Mir, Eva Montalvá, Miriam Cantos Pallarés, Preoperative Chemotherapy Plus Bevacizumab and Morbidity after Resection of Colorectal Cancer Liver Metastases , Journal of Analytical Oncology: Vol. 3 No. 1 (2014)
- Zahra Pezeshki, Mehdi Nematbakhsh, Nitric Oxide Metabolites Change in Cisplatin-Induced Nephrotoxicity: The Effect of L-Arginine and Losartan , Journal of Analytical Oncology: Vol. 2 No. 2 (2013)
- Sajad Ahmad Salati, Mohammed Alfehaid, Lamees Sulaiman Alsulaim, Saleh Ahmad Alsuwaydani, Mohammed Ahmed Elmuttalut, Uterine Metastasis from Carcinoma of Breast – A Systematic Analysis , Journal of Analytical Oncology: Vol. 12 (2023)
- Miricescu Daniela, Totan Alexandra, Calenic Bogdan, Parlatescu Ioanina, Mohora Maria, Greabu Maria, Salivary Diagnosis: Detection of Several Intracellular Enzymes in Patients with Oral Lichen Planus , Journal of Analytical Oncology: Vol. 2 No. 3 (2013)
You may also start an advanced similarity search for this article.